Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma

Experimental Hematology

Volumn 34, Issue 5, 2006, Pages 688-694

  Kröger, Nicolaus ^a   Zagrivnaja, Maria ^a   Schwartz, Sabine ^a   Badbaran, Anita ^a   Zabelina, Tatjana ^a   Lioznov, Michael ^a   Ayuk, Francis ^a   Zander, Axel ^a   Fehse, Boris ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PRIMER DNA;

ADOPTIVE IMMUNOTHERAPY; ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BIOLOGICAL MONITORING; CANCER CELL; CANCER PREVENTION; CELL KINETICS; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; DNA SEQUENCE; DONOR; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC LINE; GENETIC STABILITY; HEALTH STATUS; HOST CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; REMISSION; SAMPLE SIZE; SENSITIVITY ANALYSIS; T LYMPHOCYTE;

CHIMERA; GENETIC MARKERS; HUMANS; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 33646109316     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.01.011     Document Type: Article

References (26)

1. Corradini P., Cavo M., Lokhorst H., et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 102 (2003) 1927-1929
2. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 17 (1999) 208-215
3. Martinelli G., Terragna C., Zamagni E., et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 18 (2000) 2273-2281
4. Bensinger W.I., Buckner C.D., Anasetti C., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88 (1996) 2787-2793
5. Lokhorst H.M., Wu K., Verdonck L.F., et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103 (2004) 4362-4364
6. Ayuk F., Shimoni A., Nagler A., et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced-intensity conditioning allograft for multiple myeloma. Leukemia 18 (2004) 659-662
7. Kröger N., Sayer H.G., Schwerdtfeger R., et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation anti-thymocyte globulin is highly effective with low transplantation-related mortality. Blood 100 (2002) 3919-3924
8. Crawley C., Lalancette M., Szydlo R., et al. Chronic Leukaemia Working Party of the EBMT. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 105 (2005) 4532-4539
9. Badros A., Barlogie B., Morris C., et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 97 (2001) 2574-2579
10. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 (2003) 3447-3454
11. Galimberti S., Benedetti E., Morabito F., et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 29 (2005) 961-966
12. Serrano J., Roman J., Sanchez J., et al. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse. Blood 95 (2000) 2659-2665
13. Bader P., Beck J., Frey A., et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 21 (1998) 487-495
14. Lawler M., Humphries P., and McCann S.R. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction. Blood 77 (1991) 2504-2514
15. Ugozzoli L., Yam P., Petz L.D., et al. Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood 77 (1991) 1607-1615
16. Durnam D.M., Anders K.R., Fisher L., O'Quigley J., Bryant E.M., and Thomas E.D. Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. Blood 74 (1989) 2220-2226
17. Alizadeh M., Bernard M., Danic B., et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 99 (2002) 4618-4625
18. Maas F., Schaap N., Kolen S., et al. Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. Leukemia 17 (2003) 621-629
19. Fehse B., Chukhlovin A., Kuhlcke K., et al. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res 10 (2001) 419-425
20. Kröger N., Schwerdtfeger R., Kiehl M., et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100 (2002) 755-760
21. Tögel F., Kröger N., Korioth F., Fehse B., and Zander A.R. Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR. J Hematother 11 (2002) 971-976
22. Luft T., Moos M., Goldschmidt H., Ho A.D., and Gorner M. Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. Br J Haematol 123 (2003) 646-653
23. Griffith L.M., McCoy Jr. J.P., Bolan C.D., et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 128 (2005) 668-675
24. Bellucci R., Wu C.J., Chiaretti S., et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 103 (2004) 656-663
25. Manz R.A., Hauser A.E., Hiepe F., and Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 23 (2005) 367-386
26. Kröger N., Shimoni A., Zagrivnaja M., et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 104 (2004) 3361-3363